

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

Claim 1 (currently amended): A method of treating uveal melanoma said method comprising administering to a mammal in need of such a treatment, ~~a therapeutically effective dose of the methanesulfonate salt of~~ 4-(4-methyl piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino) phenyl]-benzamide ~~or a pharmaceutically acceptable salt thereof in a therapeutically effective dose for promoting cell death in uveal melanoma.~~

Claim 2 (previously presented): The method according to claim 1 wherein the uveal melanoma is a metastasizing uveal melanoma.

Claims 3-4 (canceled)

Claim 5 (currently amended): The method according to claim ~~[[4]]~~ 1 wherein the methanesulfonate salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide is in the beta crystal form.

Claim 6 (currently amended): The method according to claim 1 wherein the methanesulfonate salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide is administered at a daily dose corresponding to 100 mg to 1000 mg of free base.

Claim 7 (currently amended): The method according to claim 6 wherein the methanesulfonate salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide is administered once daily for a period exceeding 3 months.

Claims 8-10 (canceled)